Masked uncontrolled hypertension: Prevalence and predictors.

BACKGROUND: There are limited data on 'masked uncontrolled hypertension' (MUCH) in patients with treated and apparently well-controlled BP is unknown. OBJECTIVES: To define the prevalence and predictors of MUCH among hypertensive patients with controlled office blood pressure. METHODS: One hundred ninety-nine hypertensive patients presented to the specialized hypertension clinics at two University Hospitals. All patients had controlled office blood pressure (less than 140/90 mmHg). Patients were assessed regarding history, clinical examination, and laboratory data. All patients underwent ambulatory blood pressure monitoring (ABPM) for 24 h, within a week after the index office visit. MUCH was diagnosed if average 24-h ABPM was elevated (systolic BP ≥ 130 mmHg and/or diastolic BP ≥ 80 mmHg) despite controlled clinic BP. RESULTS: Sixty-six patients (33.2%) had MUCH according to 24-h ABPM criteria (mean age 53.5 ±â€¯9.3 years, 60.6% men). MUCH was mostly caused by the poor control of nocturnal BP; with the percentage of patients in whom MUCH was solely attributable to an elevated nocturnal BP almost double that due to daytime BP elevation (57.3% vs. 27.1%, P < 0.001). The most common predictors of MUCH were smoking, DM and positive family history of DM. CONCLUSION: The prevalence of masked suboptimal BP control is high. Office BP monitoring alone is thus inadequate to ascertain optimal BP control because many patients have an elevated nocturnal BP. ABPM is needed to confirm proper BP control, especially in patients with high cardiovascular risk profile. Smoking, DM and positive family history of DM were the most common predictors of MUCH.

Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.

Heart failure is a systemic and multiorgan syndrome with metabolic failure as a fundamental mechanism. As a consequence of its impaired metabolism, other processes are activated in the failing heart, further exacerbating the progression of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. Clinical trials have demonstrated that the adjunct of trimetazidine to the conventional medical therapy improves symptoms, cardiac function and prognosis in patients with heart failure without exerting negative hemodynamic effects. This review focuses on the rationale and clinical benefits of trimetazidine by acting on cardiac metabolism in heart failure, and aims to draw attention to the readiness of this agent to be included in all the major guidelines dealing with heart failure.

Scar characteristics for prediction of ventricular arrhythmia in ischemic cardiomyopathy.

BACKGROUND: Better risk-stratification tools are needed to identify the best candidates for implantable cardioverter defibrillator implantation. Infarct characterization by cardiac magnetic resonance (CMR) has become an evolving potential tool for risk stratification. OBJECTIVE: We assessed the ability of scar characteristics by CMR in patients with postinfarction left ventricular (LV) dysfunction to predict sustained monomorphic ventricular tachycardia (SMVT). METHODS: Forty-eight patients with postinfarction LV dysfunction underwent CMR study. Twenty-four patients had history of SMVT and the other 24 were control group and underwent electrophysiological study to assess SMVT inducibilty. Various scar characteristics were assessed in the spontaneous SMVT group and were compared with the inducible and noninducible SMVT groups. RESULTS: Only six patients in the control group had inducible SMVT. In univariable analysis, total scar (absolute and as percent of LV), scar core (absolute and as percent of LV), peri-infarct zone (absolute and as percent of LV), mean infarct transmurality, and number of segments with late gadolinium enhancement (LGE) were statistically significant predictors of spontaneous SMVT experience and SMVT inducibility. In multivariable analysis, total infarct as percent of LV mass was the only significant independent predictor of spontaneous SMVT experience (odds ratio [OR] 1.33 per% change, 95% confidence interval [CI] 1.12-1.6, P = 0.001) and SMVT inducibility (OR 1.3 per% change, 95% CI 1.1-1.6, P = 0.004). CONCLUSION: Characterization of myocardial infarct by LGE-CMR, specifically total infarct size, is better predictor of spontaneous SMVT experience and SMVT inducibility than LV ejection fraction.

Pulmonary hypertension in patients with chronic renal failure: role of parathyroid hormone and pulmonary artery calcifications.

RATIONALE: The aim of this work was to study the association of pulmonary hypertension (PH) with pulmonary artery calcifications (PACs) and hyperparathyroidism in patients with chronic renal failure (CRF) receiving regular hemodialysis. BACKGROUND: Scarce data are available regarding the prevalence and the predictors of PH in patients with CRF. Abnormal (99m)Tc diphosphonate lung uptake was reported in these patients, suggesting a role of PACs. METHODS: We studied 51 patients (28 men and 23 women) with end-stage renal disease, who were receiving regular hemodialysis. Patients underwent two-dimensional, Doppler echocardiographic imaging. Laboratory investigations included BUN, serum creatinine, calcium, phosphorus, alkaline phosphatase, and intact molecule parathormone. PH was defined as pulmonary artery systolic pressure > 35 mm Hg as determined by Doppler echocardiographic evaluation. RESULTS: PH was detected in 15 patients (29%). Women had a higher prevalence of PH (48% vs 14%, p = 0.01). There was no significant differences between patients with PH and those without PH with regards to age, duration of dialysis, serum calcium (9.6 +/- 2 mg/dL vs 10 +/- 2 mg/dL), phosphorus (6 +/- 1.4 mg/L vs 6.2 +/- 1.9 mg/L), alkaline phosphatase (609 +/- 768 U/L vs 473 +/- 574 U/L), parathyroid hormone (PTH) [420 +/- 512 pg/mL vs 354 +/- 519 pg/mL] or the prevalence of an abnormal (99m)Tc diphosphate lung scan result (60% vs 73%, respectively [+/- SD]). CONCLUSIONS: This study demonstrated that 29% of patients with CRF receiving regular hemodialysis have PH. The presence of PH was not related to the level of PTH or the severity of other metabolic abnormalities. There was no relation between PH and the presence or the severity of PAC. PH is detected more frequently in women. This study does not support a role of secondary hyperparathyroidism and subsequent PAC as the etiology of PH in patients with CRF.